세계의 혈관운동성 갱년기 증상(VMS) 치료 시장 보고서(2025년)

Vasomotor menopausal symptoms (VMS) treatment involves medical interventions and therapies aimed at alleviating or managing the range of symptoms associated with menopause. These symptoms, experienced by women during menopause, include hot flashes and night sweats. The treatment approach focuses on rebalancing hormone levels in the body and modifying neurotransmitters in the brain.

The primary categories of medications used in vasomotor menopausal symptoms (VMS) treatment include antidepressants like fluoxetine, paroxetine, and sertraline, hormone therapy, anticonvulsants such as phenytoin and phenobarbital, and others. Antidepressants constitute a class of drugs primarily prescribed to address depression and certain other mental health conditions. These medications are available through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, catering to different end-users such as hospitals, specialty clinics, and homecare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The vasomotor menopausal symptoms (VMS) treatment market research report is one of a series of new reports from The Business Research Company that provides vasomotor menopausal symptoms (VMS) treatment market statistics, including vasomotor menopausal symptoms (VMS) treatment industry global market size, regional shares, competitors with a vasomotor menopausal symptoms (VMS) treatment market share, detailed vasomotor menopausal symptoms (VMS) treatment market segments, market trends and opportunities and any further data you may need to thrive in the vasomotor menopausal symptoms (VMS) treatment industry. This vasomotor menopausal symptoms (VMS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vasomotor menopausal symptoms (vms) treatment market size has grown strongly in recent years. It will grow from $17.86 billion in 2024 to $19.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand.

The vasomotor menopausal symptoms (vms) treatment market size is expected to see strong growth in the next few years. It will grow to $24.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt).

The forecast of 6.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. menopausal care by inflating prices of non-hormonal neurokinin-3 antagonists and cooled radiofrequency devices developed in Denmark and Japan, resulting in prolonged symptom suffering and higher gynecology specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The expansion of the vasomotor menopausal symptoms treatment market is fueled by the increasing menopausal population. Menopause, a natural biological phase signifying the end of a woman's reproductive years, typically occurs between the ages of 45 and 55, with an average age of around 51. The growing number of menopausal women worldwide seeking treatment for symptoms like hot flashes and vaginal dryness is a key factor propelling the growth of treatments for vasomotor menopausal symptoms (VMS). For example, data from the Cuyuna Regional Medical Center, a U.S.-based organization, indicates that due to increased life expectancy, an estimated 1.1 billion women will reach menopause by 2025. Additionally, the menopausal population is projected to grow by 1.6% annually until 2060. Hence, the expanding menopausal demographic is a driving force behind the vasomotor menopausal symptoms treatment market's growth.

Government initiatives focused on women's health during menopause are set to drive the growth of the vasomotor menopausal symptoms treatment market. These initiatives encompass funding for innovative research on various aspects of the menopausal transition, disease prevention, and pharmacological, clinical, and epidemiological investigations. Such efforts are part of broader women's health initiatives that address a wide range of concerns. As an illustration, the Government of New South Wales, an Australia-based government agency, has allocated $40.3 million over four years (from 2022-2023 to 2025-2026) to establish up to 16 new programs aimed at assisting women experiencing severe menopausal symptoms. Therefore, these government initiatives focusing on women's health during menopause are propelling the growth of the market for vasomotor menopausal symptoms treatment.

Prominent companies engaged in the vasomotor menopausal symptoms treatment market are prioritizing the development of products like Veozah and securing approvals to offer new treatment alternatives that address unmet medical requirements for patients. The approval of novel drugs for menopausal symptom management presents advantages in terms of improved efficacy and safety compared to existing treatments. For example, in May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received FDA approval for Veozah (fezolinetant) 45 mg, designed to be taken once daily, for the treatment of menopausal vasomotor symptoms (VMS), spanning from mild to severe. Veozah is the first nonhormonal neurokinin 3 (NK3) receptor antagonist authorized for managing menopausal-related VMS. This hormone-free option functions by blocking a neural pathway involved in regulating these symptoms. Veozah provides an alternative treatment choice, particularly for women experiencing such symptoms who either cannot or prefer not to use hormone therapy. The approval of Veozah underscores its potential as a novel drug for addressing menopausal symptoms.

In March 2022, Amyris Inc., a U.S.-based biotechnology firm, acquired MenoLabs LLC for $35.4 million. This acquisition enables Amyris to broaden its presence in the women's health market, gain access to new technologies and capabilities, and acquire a dedicated customer base. MenoLabs LLC, a U.S.-based women's health and technology company, specializes in the development of dietary supplements designed to alleviate menopause symptoms in women.

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vasomotor menopausal symptoms (VMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vasomotor menopausal symptoms (VMS) treatment market consists of revenues earned by entities by providing services such as cognitive-behavioral therapy, acupuncture, lifestyle modifications, herbal and vitamin supplements and complementary and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasomotor menopausal symptoms (VMS) treatment market also includes sales of natural supplements, cooling products, vaginal estrogen products, stress-reduction products, sleep aids and dietary supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vasomotor menopausal symptoms (vms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vasomotor menopausal symptoms (vms) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vasomotor menopausal symptoms (vms) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes
• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors); SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors); TCAs (Tricyclic Antidepressants); MAOIs (Monoamine Oxidase Inhibitors); Atypical Antidepressants
• 2) By Fluoxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
• 3) By Paroxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
• 4) Sertraline: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
• 5) Hormone Therapy: Estrogen Replacement Therapy (ERT); Progestin Therapy; Combined Hormonal Therapy (CHT); Testosterone Replacement Therapy (TRT)
• 6) Anticonvulsant: Hydantoins; Barbiturates; Benzodiazepines; Valproates; Succinimides; Carboxylic Acid Derivatives
• 7) Phenytoin: Hydantoins
• 8) Phenobarbital: Barbiturates
• 9) Other Drug Classes: Antibiotics; Analgesics; Antidiabetics; Antihypertensives; Anticoagulants; Immunosuppressants; Antipsychotics; Antihistamines
• Companies Mentioned: Pfizer Inc.; Abbvie Inc.; Novartis AG; Ausio Pharmaceuticals LLC; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Kyowa Kirin Co. Ltd.; Dr. Reddy's Laboratories Ltd.; Alembic Pharmaceuticals Limited Inc.; Apotex Inc.; Hikma Pharmaceutical plc; Endo Pharmaceuticals plc; Amneal Pharmaceuticals LLC; Mundipharma International Ltd.; Lupin Limited; Glenmark Pharmaceuticals Ltd.; Hisamitsu Pharmaceutical Co. Inc.; Zhejiang Huahai Pharmaceutical Co. Ltd.; Emcure Pharmaceuticals Limited; Wockhardt Pvt. Ltd.; QuatRx Pharmaceuticals Company; Bionovo Inc.; Mithra Pharmaceuticals SA; EndoCeutics Inc.; Zydus Group; Edgemont Pharmaceuticals LLC; MenoGeniX Inc.; Agile Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Characteristics

3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies

4. Vasomotor Menopausal Symptoms (VMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Growth Rate Analysis
• 5.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vasomotor Menopausal Symptoms (VMS) Treatment Total Addressable Market (TAM)

6. Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation

• 6.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressants
• Fluoxetine
• Paroxetine
• Sertraline
• Hormone Therapy
• Anticonvulsant
• Phenytoin
• Phenobarbital
• Other Drug Classes
• 6.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• SSRIs (Selective Serotonin Reuptake Inhibitors)
• SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
• TCAs (Tricyclic Antidepressants)
• MAOIs (Monoamine Oxidase Inhibitors)
• Atypical Antidepressants
• 6.5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Depression
• Obsessive-Compulsive Disorder (OCD)
• Panic Disorder
• Generalized Anxiety Disorder (GAD)
• Post-Traumatic Stress Disorder (PTSD)
• Social Anxiety Disorder
• Premenstrual Dysphoric Disorder (PMDD)
• 6.6. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Depression
• Obsessive-Compulsive Disorder (OCD)
• Panic Disorder
• Generalized Anxiety Disorder (GAD)
• Post-Traumatic Stress Disorder (PTSD)
• Social Anxiety Disorder
• Premenstrual Dysphoric Disorder (PMDD)
• 6.7. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Depression
• Obsessive-Compulsive Disorder (OCD)
• Panic Disorder
• Post-Traumatic Stress Disorder (PTSD)
• Social Anxiety Disorder
• Premenstrual Dysphoric Disorder (PMDD)
• 6.8. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Replacement Therapy (ERT)
• Progestin Therapy
• Combined Hormonal Therapy (CHT)
• Testosterone Replacement Therapy (TRT)
• 6.9. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydantoins
• Barbiturates
• Benzodiazepines
• Valproates
• Succinimides
• Carboxylic Acid Derivatives
• 6.10. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenytoin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydantoins
• 6.11. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenobarbital, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Barbiturates
• 6.12. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Analgesics
• Antidiabetics
• Antihypertensives
• Anticoagulants
• Immunosuppressants
• Antipsychotics
• Antihistamines'

7. Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional And Country Analysis

• 7.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 8.1. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 9.1. China Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 9.2. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 10.1. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 11.1. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 11.2. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 12.1. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 13.1. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 14.1. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 14.2. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 15.1. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 15.2. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 16.1. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 17.1. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 18.1. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 19.1. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 20.1. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 21.1. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 21.2. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 22.1. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 23.1. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 23.2. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 24.1. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 24.2. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 25.1. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 25.2. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 26.1. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 26.2. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 27.1. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 28.1. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 28.2. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market

• 29.1. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
• 29.2. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape
• 30.2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Ausio Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Vasomotor Menopausal Symptoms (VMS) Treatment Market Other Major And Innovative Companies

• 31.1. Mylan N.V.
• 31.2. Sun Pharmaceutical Industries Ltd.
• 31.3. Aurobindo Pharma Limited
• 31.4. Kyowa Kirin Co. Ltd.
• 31.5. Dr. Reddy's Laboratories Ltd.
• 31.6. Alembic Pharmaceuticals Limited Inc.
• 31.7. Apotex Inc.
• 31.8. Hikma Pharmaceutical plc
• 31.9. Endo Pharmaceuticals plc
• 31.10. Amneal Pharmaceuticals LLC
• 31.11. Mundipharma International Ltd.
• 31.12. Lupin Limited
• 31.13. Glenmark Pharmaceuticals Ltd.
• 31.14. Hisamitsu Pharmaceutical Co. Inc.
• 31.15. Zhejiang Huahai Pharmaceutical Co. Ltd.

32. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

34. Recent Developments In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

35. Vasomotor Menopausal Symptoms (VMS) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer